Clinical Supplies Sample Clauses

Clinical Supplies. As applicable for the Protocol, Sponsor shall make available sufficient quantities of Study Drug free of charge to carry out the Study, it being understood that Institution and Principal Investigator shall take responsibility for and reasonable steps to maintain appropriate records and assure appropriate supply, handling, storage, distribution and usage of the Study Drug and any other Sponsor provided materials, including but not limited to equipment, in accordance with the Protocol and any applicable laws and regulations relating thereto. Institution and Principal Investigator will not use for any other purpose or conduct any other research activities with the Study Drug provided under this Agreement or the materials provided under this Agreement than that stated in the Protocol. All unused Study Drug and Sponsor provided materials will be returned to Sponsor by Institution or Principal Investigator at the conclusion of the Study, or upon earlier termination of this Agreement, unless written authorization to destroy or retain them is given by Sponsor. If authorization to destroy unused Study Drug or Sponsor provided material is given, Institution or Principal Investigator shall provide Sponsor with documentation of the method of destruction. Sponsor shall own all right, title and interest in any and all material purchased or provided at the expense of Sponsor under this Agreement. Institution and/or Principal Investigator shall secure that the disposing of the Study Drug is in full compliance with the applicable legal regulations and guidelines of good pharmacy practice as laid down in Decree No. 84/2008 Coll. For this purpose Institution and/or Principal Investigator shall enter into a legally binding agreement with an appropriately qualified pharmacist/pharmacist assistant or a pharmacy and/or take any other appropriate measures. In this connection, Institution and/or Principal Investigator shall provide Sponsor with at least the name and address of the pharmacist/pharmacist assistant or business name and address of the pharmacy, including name of a leading pharmacist, as appropriate, no later than 15 days before the commencement of the Study at the Institution. Sponsor may use the provided information only for the purpose of the Study. 12. Indemnification and Insurance předpokladu, že taková pojistná smlouva je součástí Smlouvy). 11. Klinické dodávky Tak jak se použije pro Protokol, Zadavatel zajistí dostatečné množství Hodnoceného léčivého přípravku z...
Clinical Supplies. As applicable for the Protocol, Sponsor shall make available sufficient quantities of Study Drug free of charge to carry out the Study, it being understood that Institution and Principal Investigator shall take responsibility for and reasonable steps to maintain appropriate records and assure appropriate takeover, handling, storage, distribution and usage of the Study Drug and any other Sponsor provided materials, including but not limited to equipment, in accordance with the Protocol and any applicable laws and regulations relating thereto. Institution and Principal Investigator will not use for any other purpose or conduct any other research activities with the Study Drug provided under this Agreement or the materials provided under this Agreement than that stated in the Protocol. All unused Study Drug and Sponsor provided materials will be returned to Sponsor by Institution or Principal Investigator at the conclusion of the Study, or upon earlier termination of this Agreement, unless written authorization to destroy or retain Smlouva je povinně uveřejňovaným dokumentem podle zákona č. 340/2015 Sb. (zákon o registru smluv). Strany se dohodly, že uveřejnění této Smlouvy prostřednictvím registru smluv podle § 5 odst. 1 citovaného zákona bude provedeno Zdravotnickým zařízením bez zbytečného odkladu, nejpozději však do 20 dnů od jejího uzavření. Zadavatel doručí Zdravotnickému zařízení bez zbytečného odkladu konečnou verzi dokumentů (se znečitelněnými částmi), které jsou předmětem uveřejnění. Zadavatel ani Hlavní zkoušející nejsou oprávněni k uveřejnění této Smlouvy, ledaže Zdravotnické zařízení tak ve stanovené lhůtě (jak je uvedena výše) neučiní. V takovém případě převezme Zadavatel odpovědnost za uveřejnění. Strany jsou srozuměny s tím, že informace tvořící obchodní tajemství Stran a další informace, které nepodléhají povinnosti uveřejnění, budou před odesláním Smlouvy k uveřejnění znečitelněny. S ohledem na uvedené Strany souhlasí s tím, že Zadavatel před uveřejněním zajistí ochranu osobních údajů (včetně jména a příjmení, jakéhokoliv typu identifikačních údajů, dat narození, adres bydliště, telefonních čísel, bankovních účtů apod.) jakékoli fyzické osoby zmíněné ve Smlouvě v souladu s právními předpisy na ochranu osobních údajů a znečitelní zejména počet Subjektů hodnocení zařazených do Studie, plánovaná data zahájení a ukončení Studie uvedená ve Smlouvě, jakož i jakoukoliv důvěrnou informaci Zadavatele anebo vztahující se ke Studii obsaženou v Protokol...
Clinical Supplies. Subject to the terms of this Agreement, Isconova shall manufacture and supply to Genocea all Licensed Adjuvants required for the Manufacture of Clinical Supplies necessary for Clinical Trials and all other Development activities, including pre-clinical research. The terms of supply of Clinical Supplies pursuant to this Section are set forth in Exhibit C-2.
Clinical Supplies. 4.1 Unless otherwise specified in a Project Exhibit to this Agreement, Corcept will supply the clinical investigators with Study Drugs and other clinical drug supplies as are agreed upon by Scirex and Corcept for the timely completion of the Projects, and will direct the shipment of any such supplies to the location indicated by Scirex, within a reasonable time after receipt of notification from Scirex of the need for any such clinical
Clinical Supplies. Immtech shall manufacture or cause to be manufactured all Clinical Supplies of Product for the Development Program, including the completion of pre-clinical work and human clinical trials. Immtech’s choice of such Third Party contract manufacturer(s) for the Product, and the terms and conditions of such manufacturing and supply agreement(s) for the Product, shall be subject to reasonable prior review by the Development Committee (which includes the reasonable input of Par).
Clinical Supplies. Connetics shall, and shall cause its Contract Manufacturer(s) to, commencing from the Effective Date until Faulding receives Regulatory Approval to market the Product in the Territory, use Commercially Reasonable Efforts to manufacture for and supply to Faulding, and Faulding shall (subject to the terms of this Agreement) purchase, all Faulding's required quantities of Relaxin Materials for use in Clinical Development; including quantities required for any special access schemes or compassionate use programs in the Territory, provided that Faulding shall not transfer the Relaxin Materials or Product to any Third Party at any time except to the extent transfer is required for Clinical Development, Regulatory Filings or Regulatory Approval or compassionate use programs or special access schemes related to the Product in the Field and Territory. The price for Product and/or Relaxin Materials pursuant to this Section shall equal [*****].
Clinical Supplies. For clinical supplies, Teva shall deliver to Alexza a Purchase Order for the required quantities of the Product. The Parties will mutually agree on a delivery date of clinical supplies, which will depend on the special requirements (e.g., dose strength, labeling, and packaging) and Teva’s demand priority with respect to then-existing Teva orders under this Section 6.14.
Clinical Supplies. Syntex shall manufacture for Unimed approximately 500 bottles of 100 tablets each of the Product for use by Unimed in the Studies. Such Product shall be delivered to Unimed in accordance with the timing schedule set forth in Appendix C. Syntex will mark and score such Product in accordance with written instructions from Unimed.